Manitou Investment Management Ltd. Sells 4,004 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Manitou Investment Management Ltd. has reduced its stake in Edwards Lifesciences Corporation by 2.1%, selling 4,004 shares, which now makes their total holding 185,652 shares valued at approximately $14.5 million.
• Recent transactions by insiders include VP Daniel J. Lippis selling 4,114 shares, and insider Larry L. Wood selling 8,950 shares, indicating a decrease in their holdings.
• Analysts have a consensus rating of "Moderate Buy" for Edwards Lifesciences, with target prices raised by multiple firms, reflecting confidence in the stock's future performance.

Manitou Investment Management Ltd. reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 185,652 shares of the medical research company's stock after selling 4,004 shares during the period. Edwards Lifesciences accounts for approximately 2.8% of Manitou Investment Management Ltd.'s investment portfolio, making the stock its 13th biggest position. Manitou Investment Management Ltd.'s holdings in Edwards Lifesciences were worth $14,520,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its position in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after acquiring an additional 145 shares in the last quarter. Pacific Capital Partners Ltd bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $1,760,000. Czech National Bank raised its position in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company's stock worth $11,214,000 after acquiring an additional 7,917 shares in the last quarter. Dynamic Advisor Solutions LLC raised its position in shares of Edwards Lifesciences by 2.4% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company's stock worth $1,124,000 after acquiring an additional 370 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company's stock worth $5,582,000 after acquiring an additional 9,188 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Piper Sandler boosted their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. William Blair raised Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Finally, Argus raised Edwards Lifesciences to a "strong-buy" rating in a research report on Thursday, July 10th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.06.

Edwards Lifesciences Price Performance

EW stock opened at $74.02 on Friday. The company has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a price-to-earnings-growth ratio of 3.55 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00. The business has a 50-day simple moving average of $78.09 and a two-hundred day simple moving average of $76.13.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company's quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.